MK-801 inhibits the micturition reflex in chronic bladder irritation caused by crystalluria in the rat.
Urodynamic and pharmacological studies were performed to investigate the effect of crystalluria on the micturition reflex and the involvement of glutamatergic transmission. The rats, which were given LP-805 (100 mg/kg/day) orally for 12 days, voided crystalluria. The pH of these crystalluria (LP-805 urine) was the same as normal urine. The amount of crystals was 70-100/division magnified 400 x. The end of the crystals was sharp. Intravesical administration of LP-805 urine induced hyperreflexia of the micturition reflex in normal rats. When the infusion solution was changed to LP-805 urine from saline, the latency was reduced to 57.6+/-2.1% of control in single cystometrogram (CMG) or was reduced to 51.4+/-0.9% of control in continuous CMG. The voiding volume was reduced to 52.1+/-3.6% of control in single CMG or was reduced to 62.5+/-0.8% of control in continuous CMG. These parameters were recovered after LP-805 urine was removed. Intravesical administration of acetic acid did not induce hyperreflexia of the micturition reflex in LP-805-treated rats. These data suggest that the chronic irritation by aculeate crystals might induce hyperreflexia of the micturition reflex, which increase afferent neuronal activity. Intravenous administration of MK-801 (0.001 to 1 mg/kg) inhibited the micturition reflex in a dose-dependent manner. The ID50 in LP-805-treated rats (0.03 mg/kg i.v.) was lower than that in normal rats (0.56 mg/kg i.v.). After chronic irritation of the bladder epithelium, MK-801 sensitivity was enhanced for the micturition reflex. These data suggested that crystalluria elicit hyperreflexia in the micturition reflex that mediated with NMDA glutamatergic receptors.
Department of Physiology, School of Medicine, Akita University, 1-1-1 Hondo, Akita 010-8543, Japan. fishida@med.akita-u.ac.jp
Fumitaka
F
Ishida
Tomoya
T
Sato
Michiru
M
Imaizumi
Norio
N
Funayama
Kenji
K
Ikegami
Toshie
T
Nimura
Masahito
M
Kawatani
D000818:Animals; D002908:Chronic Disease; D003460:Crystallization; D018856:Cystitis, Interstitial / Q000139:chemically induced / Q000188:drug therapy*; D016291:Dizocilpine Maleate / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D011720:Pyrazoles / Q000633:toxicity; D011743:Pyrimidines / Q000633:toxicity; D051381:Rats; D017208:Rats, Wistar; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000502:physiology; D012018:Reflex / Q000187:drug effects / Q000502:physiology; D001745:Urinary Bladder Diseases / Q000139:chemically induced / Q000188:drug therapy; D014554:Urination / Q000187:drug effects* / Q000502:physiology
D011720:Pyrazoles; D011743:Pyrimidines; D016194:Receptors, N-Methyl-D-Aspartate; C073993:8-tert-butyl-6,7-dihydropyrrolo(3,2-e)-5-methylpyrazolo(1,5-a)pyrimidine-3-carbonitrile; D016291:Dizocilpine Maleate